#China #Shanghai #Alebund #Hyperphosphatemia #AP306

Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306 for Hyperphosphatemia

On July 21, 2026, Alebund Pharmaceuticals (Jiangsu) Limited, also known as Alebund, announced a significant milestone in its clinical research with the first participant randomized and dosed in a global Phase IIb clinical trial of its drug candidate AP306. This trial is focused on patients experiencing hyperphosphatemia due to maintenance hemodialysis, a common complication faced by those with chronic kidney disease (CKD).

Trial Overview

The global Phase IIb multi-regional clinical trial aims to establish the efficacy and safety of AP306, which is a first-in-class oral pan-phosphate transporter inhibitor. Unlike traditional phosphate binders that operate within the gut, AP306 inhibits crucial intestinal phosphate transporters, providing a promising alternative for managing phosphate levels. The trial will be conducted at various clinical sites across the United States and China, co-sponsored by Alebund and R1 Therapeutics, Inc.

Design of the Trial: The trial will enroll approximately 168 participants, utilizing a double-blind, placebo-controlled methodology. Participants will be divided into six different dosing regimens of AP306 or a placebo. The treatment period is set for eight weeks, during which the primary endpoint will assess the change in serum phosphate levels from baseline to the conclusion of treatment. Secondary endpoints include the percentage of patients achieving target phosphate levels and the timeline needed for phosphate control.

The trial is particularly timely, as it arrives amid a growing need for effective hyperphosphatemia treatments. Even with existing therapies, many dialysis patients continue to exceed target phosphate levels, with about 76% of such patients in China and significant numbers elsewhere remaining outside therapeutic ranges.

Unmet Medical Need

Hyperphosphatemia poses serious risks, including vascular calcification and enhanced cardiovascular events, affecting around 95% of CKD patients on dialysis. Current standard care, involving dietary phosphate restrictions and available phosphate binders, frequently proves inadequate. As the global dialysis population is expected to increase sharply—growing from approximately 1.3 million in 2025 to around 3.4 million in 2035 in China—the demand for more effective treatments is becoming urgent.

Such treatments must balance efficacy with tolerability and ease of use since existing options often lead to gastrointestinal issues, high pill burdens, and poor adherence over time. Studies indicate that innovative therapies are crucial as they address the significant gaps in current treatment landscapes.

Promising Past Results

In earlier Phase II trials conducted in China, AP306 showcased encouraging results, achieving superior reductions in serum phosphate levels when compared with traditional treatments such as sevelamer carbonate. Patients treated with AP306 exhibited a mean reduction of 2.51 mg/dL compared to just 1.08 mg/dL for the comparator group. Adverse effects primarily included mild gastrointestinal issues that were generally manageable.

Breathing optimism into the ongoing developments, the National Medical Products Administration granted AP306 Breakthrough Therapy Designation in June 2024, further highlighting its potential to provide critical solutions for CKD patients struggling with hyperphosphatemia.

Collaboration and Future Potential

Alebund's partnership with R1 Therapeutics will enable collaborative advancement in the clinical study and regulatory efforts. Under their licensing agreement, Alebund maintains exclusive rights in several key markets, while R1 oversees operations outside of these areas, enhancing the prospects for global impact in treating hyperphosphatemia.

Alebund Pharmaceuticals, listed on the Hong Kong Stock Exchange under the code 09637, remains dedicated to advancing kidney health solutions through its extensive pipeline and integrated development strategies. With AP306 progressing through crucial phases of development, the company is poised to contribute significantly to the evolving landscape of renal pharmaceutical care.

For more information, visit Alebund Pharmaceuticals.